Diabetic Retinopathy Market To Reach $13.77 Billion By 2030

Diabetic Retinopathy Market Growth & Trends

The global diabetic retinopathy market size is expected to reach USD 13.77 billion by 2030, registering a CAGR of 6.43% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of diabetes, growing geriatric population, and increasing prevalence of blindness due to diabetes are the major factors anticipated to boost market growth over the forecast period. Growth in the market is further propelled by the increasing awareness about diabetes management & care and new product launches. Diabetic retinopathy is caused by damage to the blood vessels in the retina, which leads to blurred vision and vision loss in most cases.

The increase in prevalence of diabetes due to aging, obesity, and unhealthy lifestyles is contributing to the growth of the market. Obesity is a major factor leading to diabetes. According to WHO, in 2021, around 39% of adults aged 18 years and above were overweight, and 13% were obese worldwide. In addition to obesity, diabetes is becoming increasingly prevalent globally. The International Diabetes Federation (IDF) estimated l537 million adults (aged 20 to 79 years) were living with diabetes in 2021, which is expected to rise to 642 million by 2040. The IDF also reports that the prevalence of diabetes is increasing globally, with the highest increases witnessed in low- and middle-income countries. In 2021, the regions with the highest number of adults living with diabetes were the Western Pacific (167 million), South Asia (88 million), and Europe (59 million).

The rising geriatric population is a significant driver of the diabetes epidemic, as diabetes in older people is directly linked with higher mortality and reduced functional status. According to WHO, 80% of older people are expected to live in low- and middle-income nations by 2050. The population is aging at a considerably higher rate than in the past. In 2020, the number of persons aged 60 years and more will outnumber children under the age of 5 years. Between 2015 and 2050, the proportion of the global population aged over 60 years will nearly double, from 12% to 22%.

 Request a free sample copy or view report summary: Diabetic Retinopathy Market Report

Diabetic Retinopathy Market Report Highlights

• Non-proliferative diabetic retinopathy accounted for the largest share, by type, in 2023. The presence of large number of patients within the bracket of less than 10 years of diabetic history contributed to the large size of this segment.

• Anti-VEGF segment accounted for the largest share, by management, in 2023. High applicability of these drugs in treatment of early diagnosis and mild to moderate cases of non-proliferative DR treatment is among the prime factors leading to segmental growth.

• The Asia Pacific market is expected to grow with the highest CAGR over the forecast period.  Large population base in this region, high prevalence of diabetes, and rising geriatric population are likely to bolster the market.

Diabetic Retinopathy Market Segmentation

Grand View Research has segmented the global diabetic retinopathy market based on type, management, and region:

Diabetic Retinopathy Type Outlook (Revenue, USD Million, 2018 - 2030)

• Proliferative Diabetic Retinopathy

• Non-proliferative Diabetic Retinopathy

Diabetic Retinopathy Management Outlook (Revenue, USD Million, 2018 - 2030)

• Anti-VEGF

• Intraocular Steroid Injection

• Laser Surgery

• Vitrectomy

Diabetic Retinopathy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Thailand

  • Australia

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List Of Key Players Diabetic Retinopathy Market

• Bayer AG

• ABBVIE INC.

• Novartis AG

• Oxurion NV

• Sirnaomics

• Alimera Sciences

• Ampio Pharmaceuticals Inc.

• BCNPeptides

• Kowa Company Ltd.

• Genentech, Inc.